Evidence map›Paper›PMID 31653147›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.

Sandeep Kumar S, Shalini N Swamy, C S Premalatha, V R Pallavi, Ramesh Gawari

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sandeep Kumar SDepartment of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India.ORCID 0000-0002-4105-6356
Shalini N SwamyDepartment of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India.ORCID https://orcid.org/00
C S PremalathaDepartment of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India.
V R PallaviDepartment of Gynaeconcology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India.
Ramesh GawariDepartment of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India.
Kidwai Memorial Institute of Oncology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOvarian cancer is one of the leading causes of cancer deaths in women. Ovarian cancer is diagnosed at the late stages and generally relapses within 12-14 months of cytoreductive surgery. This is attributed to lack of precise molecular detection methodologies to detect and track the disease. Epigenetic alteration such as aberrant promoter hypermethylation is an important early event that occurs during cancer development and progression. This study focuses on development of a minimally invasive methylation marker that could be used for detection and prognosis of ovarian cancer patients.

methodsAberrant promoter hypermethylation of RASSF1a and BRCA1 was assessed in circulating DNA of 72 EOC patients using methylation-specific PCR. The findings were correlated with various clinicopathological parameters. Statistical analysis was done using the Fisher exact test and chi-square test.

resultsThe aberrant methylation patterns of RASSF1a and BRCA1 was identified to be present in the cancerous samples. A total of 31.9 % and 56.9% methylation was observed for RASSF1a and BRCA1 respectively. A striking 50% methylation of BRCA1 was identified in the benign sample cohort, which marks the significance of assessing the hypermethylation pattern to detect cancer at its early stages. Methylation of the two tumor suppressor genes was evident across various stages and grades of ovarian tumors suggesting that this could also help as a prognostic marker.

conclusionThe results of the current study hold significance since the hypermethylation patterns can be identified in the cell-free circulating tumor DNA from a small volume of blood plasma and is a simple and minimally-invasive method. Assessment of hypermethylation patterns of a panel of TSG along with the existing screening markers could aid in better diagnosis and management of the disease. It could also aid in designing specifically tailored treatment strategies to fight the disease.

Indexed as

DNA MethylationPromoter Regions, GeneticAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBiomarkers, TumorBRCA1 ProteinCase-Control StudiesCirculating Tumor DNACystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansOvarian NeoplasmsPrognosisBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanCirculating Tumor DNARASSF1 protein, humanTumor Suppressor ProteinsBiomarkerCirculating tumor DNAOvarian CancerPromoter hypermethylationTumor suppressor genes

Identifiers

PMID31653147
PMCPMC6982682
OpenAlexW2981023617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.